Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study
First analysis data from CARTITUDE-4 demonstrated a statistically significant improvement in progression-free survival, with a hazard ratio of 0.26 CARTITUDE-4 is the first randomized study... | June 5, 2023
New Jersey United States Hemophagocytic Lymphohistiocytosis European Hematology Association Janssen Biotech Inc Medicinal Devices Agency
Source: marketscreener.com